- Charles River Laboratories has integrated Akadeum Life Sciences’ GMP-grade Human T Cell Leukopak Isolation Kit into its Cell Therapy Flex Program.
- The technology uses microbubbles to simplify T cell separation, aiming to accelerate cell therapy manufacturing.
Charles River Laboratories International, Inc. and Akadeum Life Sciences have announced the integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program.
The Flex platform provides ready-to-use solutions and validated protocols for autologous CAR-T and TCR-T cell therapies. It is designed to reduce risk, lower costs, and shorten development timelines. Automated closed systems support a range of processes from cell selection and expansion through to electroporation, viral vector methods, concentration, and fill-finish.
Akadeum’s kit employs patented Microbubble technology, which uses buoyancy to separate cells. The method enables unwanted cells to float to the surface, improving viability while avoiding the need for additional laboratory equipment or space. Procedures can be carried out directly in the provided apheresis bag.
Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing at Charles River, said: “Akadeum’s Microbubble technology provides an innovative solution for cell separation, utilising gravity to isolate T cells. This method is scalable and GMP, ensuring efficiency and quicker delivery to patients.”
Brandon McNaughton, CEO of Akadeum, added that the collaboration addresses manufacturing challenges: “Our work with Charles River and the Flex platform allows us to tackle these challenges head-on, delivering healthier cells, faster processing times, and scalable separations that reduce complexity.”
